


Survey: Impact of COVID-19 Pandemic on Rare Disease Patients in Canada

	Question	
1.	<p>At this time, to the best of your knowledge, what is the most likely impact of COVID-19 on (adequate) supply of your company's drugs to Canadian patients? If the answer varies by drug, please provide either specific drug information or respond in general across all drugs.</p>	<p>Ensuring supply for patients is a high priority for Bayer. Therefore, we have a general inventory policy which includes having buffers in place to minimize and mitigate impact on our product supply.</p> <p>At this time, we do not have an impact on production and Canadian product supply as a result of COVID-19. Our own production is running according to plan.</p>
2.	<p>If interruption or shortage in drug supply were anticipated or took place, where could Canadian patients find information about the situation and any plans for addressing or mitigating the impact? Is there a website, information line, or contact person?</p>	<p>For more information, please visit www.bayer.ca</p>
3.	<p>This question addresses any clinical trials that your company has at this time that includes Canadian sites or Canadian patients in other countries. At this time, to the best of your knowledge, have you experienced or do you anticipate any interruptions, delays, or modifications in the conduct of these trials due to COVID-19? Please describe any modifications or other adjustments.</p>	<p>During the current pandemic situation, Bayer's priority in clinical trials is to ensure patient safety as always. Bayer continues to work on our clinical trials as the situation unfolds. We are proactively working with clinical trial sites to ensure patient recruitment, patient visits and patient drug supplies can continue in a safe manner while also ensuring compliance to regulations and integrity of clinical data. In some specific cases recruitment has been halted temporarily.</p>
4.	<p>To the best of your knowledge, are there any clinical trials that will not take place or will be delayed as a result of COVID-19? Please describe.</p>	<p>Bayer continues to move forward with our clinical pipeline taking into consideration clinical site staff availability, patient willingness and safety to participate in clinical trials during the COVID-19 situation.</p>
5.	<p>Where can patients find information about any increased risk of getting COVID-19 or increased impact of COVID-19 due to any medications provided by your company?</p>	<p>Patients can speak with their treating physician or other supporting healthcare practitioner about their individual condition and treatments. For medical inquiries regarding prescription pharmaceutical products, such as dosage and administration, approved uses, ingredients and quality complaints can be directed to Bayer Drug Safety and Medical Information. Contact details can be found at:</p>

		https://www.bayer.ca/en/products/drug-safety-medical-information/
6.	To the best of your knowledge, are there any changes in patient support programs that are anticipated or planned, related to issues due to COVID-19? Please describe.	Bayer Inc. understands that patients who are benefiting from our products may lose their employer health insurance coverage due to hardships caused by the COVID-19 pandemic. Patients who are already enrolled in one of our patient support programs will be assured of support in the event their coverage is impacted, at minimum, until August 31, 2020.
7.	How can patients or patient organizations find updated information about your company's policies, plans, or actions related to COVID-19? How will you communicate with patients or patient groups?	For more information, please visit www.bayer.ca
8.	Is there any other information that you wish to communicate share at this time?	